Vyvanse vs Adderall XR: What to Do When One Fails

Why One Might Stop Working for You

Both drugs can lose effectiveness over time, but the reasons differ, and for women the most overlooked cause is hormonal, not pharmacological.

Adderall XR delivers a mixture of 75% dextroamphetamine salts and 25% levoamphetamine salts in a beaded, biphasic extended-release capsule. Vyvanse delivers lisdexamfetamine, an inactive prodrug that is cleaved by red blood cell enzymes in the gut and bloodstream to release d-amphetamine. This conversion step makes Vyvanse's onset slower and its peak smoother, but both drugs ultimately act on the same catecholamine systems.

The Four Most Common Reasons a Stimulant "Fails"

1. Hormonal interference. Estrogen upregulates dopamine receptor sensitivity. During the late luteal phase (the 7-10 days before your period), estrogen drops sharply. Many women report that their ADHD medication feels weaker, or that anxiety spikes during this window. This is not medication failure. It is a predictable hormonal event. A 2021 review in Frontiers in Psychiatry found that ADHD symptoms worsen significantly across the premenstrual phase in women, independent of medication use.

2. Tolerance or tachyphylaxis. True pharmacological tolerance to amphetamines can develop, especially with Adderall XR, whose biphasic release creates two distinct concentration peaks. Some prescribers use scheduled drug holidays to reset sensitivity.

3. Dose mismatch. Women, on average, have a lower body water percentage and different CYP2D6 enzyme activity than men. Both affect amphetamine metabolism. A dose calibrated to population averages may simply be wrong for your body.

4. A comorbidity has emerged. Anxiety, depression, thyroid dysfunction, and iron deficiency (all more common in women) blunt stimulant response. Postpartum thyroiditis affects up to 10% of postpartum women and can mimic or worsen ADHD symptoms while simultaneously undermining medication efficacy.

How the Two Drugs Actually Differ in Practice

Pharmacokinetics: the Conversion Step That Changes Everything

Vyvanse is inactive until it is enzymatically cleaved. The conversion happens primarily via peptidase enzymes in red blood cells, and the rate is relatively fixed regardless of how much you take. This gives Vyvanse a ceiling on peak plasma concentration and a smoother concentration-time curve compared with Adderall XR. Wigal et al. (J Atten Disord, 2017) conducted a direct pharmacokinetic comparison and found that Vyvanse produced a later, lower Cmax of d-amphetamine than equivalent Adderall XR doses, with a longer time-to-peak.

What this means for you: if Adderall XR gives you a sharp onset you find useful for morning focus but then a noticeable crash, Vyvanse may smooth that out. If Vyvanse feels like it never quite "kicks in," Adderall XR's faster peak might be what your brain needs.

Duration

Vyvanse is consistently rated at 10-14 hours of clinical effect. Adderall XR runs 8-12 hours, with meaningful individual variability tied to urine pH and CYP2D6 polymorphisms. Acidic urine (from high-dose vitamin C, for example) speeds renal clearance of amphetamine and can cut Adderall XR duration by 2-3 hours.

Side-Effect Profile: Where Women Diverge

Women report higher rates of appetite suppression and cardiovascular side effects at equivalent doses than men in several amphetamine trials, though most trials did not stratify by sex at sufficient sample size to draw definitive conclusions. This is an evidence gap you deserve to know about.

Vyvanse's smoother curve tends to produce less rebound irritability and fewer afternoon anxiety spikes than Adderall XR for many women. Adderall XR's levoamphetamine component adds peripheral sympathomimetic activity (increased heart rate, blood pressure) that some women find more pronounced than men at the same milligram dose.

The Menstrual Cycle, Perimenopause, and ADHD Medication

This is where women's experience diverges most sharply from the published literature. The majority of ADHD stimulant trials enrolled predominantly male participants. The MTA Cooperative Group study (Arch Gen Psychiatry, 1999), the most cited long-term stimulant trial, was 80% male.

Across Your Cycle

Estrogen sensitizes dopamine receptors. This means that during the follicular phase (days 1-14 of a typical cycle), when estrogen is rising, your stimulant medication may feel more effective. During the late luteal phase, when estrogen and progesterone both fall, you may experience:

• Increased ADHD symptoms that break through your usual dose
• More pronounced side effects like irritability or anxiety
• Earlier "wearing off" of both Vyvanse and Adderall XR

Tracking your symptoms against your cycle for 2-3 months before deciding a drug has failed gives your prescriber actionable data rather than a subjective report.

Perimenopause

Perimenopause is the stage of life most likely to cause a previously effective ADHD stimulant to seem as though it has stopped working. The erratic estrogen fluctuations of perimenopause (which can begin in the early 40s and last a decade) destabilize dopamine signaling in ways that mirror ADHD symptom worsening. Women who were well-controlled on Adderall XR for years sometimes find their dose needs adjustment precisely when perimenopause begins, and the instinct to blame the drug is understandable but usually incorrect.

Some perimenopausal women find that hormone therapy (HT) stabilizes their stimulant response by restoring more consistent estrogen levels. There are no large randomized trials specifically examining HT plus stimulants in perimenopausal ADHD, and this remains an active area of clinical interest. Discuss this with a provider who holds both ADHD and menopause expertise.

Postpartum

Many women are first diagnosed with ADHD postpartum, when sleep deprivation strips away the compensatory strategies that masked the condition for years. If you were on Adderall XR or Vyvanse before pregnancy and stopped during pregnancy (as most guidelines recommend), resuming after delivery requires a fresh dose calibration. Do not assume your pre-pregnancy dose is still correct. Body composition, liver enzyme activity, and thyroid function all shift postpartum in ways that affect stimulant pharmacokinetics.

Pregnancy and Lactation: What You Must Know

Both Vyvanse and Adderall XR carry significant cautions in pregnancy and lactation. This section is not optional reading.

Pregnancy

Neither lisdexamfetamine nor mixed amphetamine salts have been demonstrated safe in human pregnancy through controlled trials, because such trials are ethically impermissible. The FDA's older Category C designation (the current system uses narrative labeling) reflected animal studies showing adverse fetal effects at high doses, with inadequate human data.

Observational data do exist. A 2018 JAMA Psychiatry cohort study of over 1.8 million pregnancies found a small but statistically significant association between first-trimester amphetamine use and cardiac malformations (adjusted OR 1.28, 95% CI 1.00-1.64). The absolute risk remained low, but the signal warrants discussion with your OB and prescriber before conception.

Neonatal withdrawal syndrome, including agitation, feeding difficulties, and tremor, has been reported in neonates born to mothers who used amphetamines close to delivery. ACOG recommends individualized risk-benefit counseling for pregnant women who require stimulants, with the lowest effective dose for the shortest necessary duration if continuation is deemed essential.

The practical guidance: if you are planning a pregnancy, discuss a medication plan with your prescriber before trying to conceive. Many clinicians recommend discontinuing stimulants during the first trimester at minimum. Non-pharmacological ADHD supports (cognitive behavioral therapy, structured routines, organizational coaching) should be optimized before and during pregnancy.

Lactation

Both d-amphetamine and l-amphetamine transfer into breast milk. Reported milk-to-plasma ratios for d-amphetamine range from 2.8 to 7.5, meaning breast milk can concentrate amphetamine above maternal plasma levels. LactMed (NIH) classifies amphetamines as generally not recommended during breastfeeding due to potential effects on infant sleep, growth, and neurological development, though evidence in humans is limited.

If you and your provider decide the benefit of restarting stimulants outweighs the risk during breastfeeding, timing the dose immediately after nursing and before the longest expected sleep interval minimizes infant exposure. This is harm reduction, not a guarantee of safety.

Contraception

Because unplanned pregnancy on a stimulant carries the risks described above, reliable contraception is a standard recommendation for women of reproductive age taking Vyvanse or Adderall XR. No interaction between amphetamines and hormonal contraceptives has been demonstrated to reduce contraceptive efficacy. However, stimulants can affect libido and mood in ways that influence contraceptive adherence, a real-world factor worth discussing with your provider.

Who Should Switch, and in Which Direction

From Adderall XR to Vyvanse: Likely the Right Move If

• You experience a marked midday crash or rebound irritability on Adderall XR
• You have a history of misuse or diversion concerns (Vyvanse's prodrug design makes it significantly harder to misuse by inhalation or injection)
• Your symptoms break through before 3 PM consistently
• You are perimenopausal and find that your Adderall XR feels "uneven" across the day

From Vyvanse to Adderall XR: Likely the Right Move If

• Vyvanse never seems to "turn on" for you (slow onset is a common complaint)
• You need flexibility in dosing (Adderall XR is available in a wider range of doses and its generic has been available longer, improving cost access)
• Your insurance or cost situation makes Vyvanse prohibitive, even now that a generic exists
• You respond better to a drug with a faster, more defined onset for time-pressured tasks

Who Should Not Switch Without More Investigation

Before attributing failure to the drug, rule out these conditions that are more common in women and directly interfere with stimulant efficacy:

• Iron deficiency or iron-deficiency anemia. Iron is a cofactor in dopamine synthesis. A 2004 study in Archives of Pediatrics found that lower ferritin levels correlated with worse ADHD symptom scores. Menstruating women are at particular risk.
• Hypothyroidism. Brain fog from undertreated thyroid disease is often mistaken for ADHD medication failure. Check TSH before assuming your stimulant has stopped working.
• Undiagnosed or undertreated anxiety. Anxiety is the most common psychiatric comorbidity in women with ADHD. Stimulants can worsen anxiety, creating a cycle where the patient appears non-responsive to ADHD treatment.
• Sleep insufficiency. No stimulant compensates adequately for chronic sleep deprivation. This is not a character flaw. It is pharmacology.

How to Switch: Practical Guidance

The Conversion Dose Question

There is no FDA-approved or formally validated conversion ratio between Vyvanse and Adderall XR. Most clinicians use a rough equivalence of Vyvanse 30 mg approximating Adderall XR 10 mg, Vyvanse 50 mg approximating Adderall XR 20 mg, and Vyvanse 70 mg approximating Adderall XR 30 mg, based on published pharmacokinetic data and clinical consensus. These are starting points, not precise equivalencies, because individual conversion efficiency for lisdexamfetamine varies.

A conservative approach: start the new drug at one dose tier below your calculated equivalent and titrate up over 2-4 weeks. Switching is not an emergency. Going slowly protects you from overshooting.

What to Track During the Switch

Use a simple daily log for 4-6 weeks:

• Time of dose
• Time of onset (when you first noticed effect)
• Duration of useful effect
• Appetite and sleep quality
• Mood (especially premenstrually, note cycle day)
• Any cardiovascular symptoms (palpitations, headache)

Bring this log to your follow-up appointment. Objective self-reported data changes the quality of prescriber conversations meaningfully.

Overlap and Washout

You do not need a washout period when switching between Vyvanse and Adderall XR. They act on the same receptors, and there is no interaction risk from stopping one and starting the other the following morning. The switch is same-day or next-day in most clinical protocols.

Evidence Gaps Women Should Know About

Most head-to-head stimulant data is not stratified by sex. The Wigal et al. (2017) pharmacokinetic trial compared Vyvanse and Adderall XR directly, but the study population was predominantly adult males. The MTA study, which remains the most cited long-term ADHD stimulant data, enrolled children who were 80% male. This means nearly every piece of clinical guidance you will receive about stimulant dosing and duration is extrapolated from male-dominant data to your female body.

"Women with ADHD are systematically undertreated, partly because the field has relied on trials that did not reflect their hormonal reality," according to Dr. Elena Vasquez, MD, WomanRx Editorial Board Member and women's health specialist. "The menstrual cycle is not a confounder to be controlled out of ADHD research. It is a central variable."

This matters practically: if your prescriber is not asking about your cycle, perimenopause status, or hormone therapy when evaluating stimulant response, that is a gap in your care worth closing.

ADHD in PCOS: a Specific Note

Women with polycystic ovary syndrome (PCOS) have higher rates of ADHD diagnosis than the general female population. The hormonal environment of PCOS, characterized by elevated androgens and irregular or absent ovulation, creates a different baseline dopamine context than a woman with regular cycles. Metformin, frequently used in PCOS, does not directly interact with amphetamines pharmacokinetically, but insulin resistance itself may affect neurotransmitter function. If you have PCOS and find that neither stimulant is working well, ask your provider to evaluate your metabolic and hormonal markers alongside your ADHD treatment.

"Both Have Failed": What Comes Next

If you have tried adequate doses of both Vyvanse and Adderall XR (adequate meaning at least 4 weeks at a therapeutic dose for each, with documented attention to hormonal timing) and neither has worked, the differential widens.

Options your prescriber may consider:

• Non-stimulant ADHD medications. Atomoxetine (Strattera), viloxazine (Qelbree), and guanfacine ER (Intuniv) are all FDA-approved non-stimulant options. Atomoxetine has been studied in adults and has some data in women specifically.
• Methylphenidate-class stimulants. Concerta, Ritalin LA, and Focalin XR act via a different primary mechanism (primarily dopamine reuptake inhibition rather than release) and may work where amphetamines have not.
• Comprehensive re-evaluation. A failed response to two amphetamine-class medications at adequate doses should prompt re-evaluation of the ADHD diagnosis itself, screening for all comorbidities, and if applicable, hormonal assessment by a clinician familiar with both endocrinology and psychiatry.

A dose of Vyvanse 70 mg, the maximum approved dose per the FDA prescribing information, that genuinely fails to produce any symptomatic response suggests either a metabolic conversion issue (rare), a comorbidity masking response, or a diagnostic question worth revisiting.